News | January 23, 2026
Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator
This marks the second indication for which gumokimab has gained NDA review acceptance
This marks the second indication for which gumokimab has gained NDA review acceptance
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Medico Remedies has secured the order to supply Azithromycin 500gm (tablets) to Uttar Pradesh Medical Supplies Corporation Limited
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
The study evaluated patients with stage III/IV melanoma after complete tumor resection
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Subscribe To Our Newsletter & Stay Updated
